

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A method for determining a whether a subject has a modified susceptibility to cardiovascular disease comprising:
detecting in a nucleic acid sample from said subject at least one CETP allele selected from the group consisting of intron 1 (707); intron 8 (3707); intron 8 (3946); promoter (VNTR); insertion (307); and intron 15 (493),
wherein said CETP allele is associated with a modified level of CETP activity.
2. (Original) A method as defined in claim 1 wherein said cardiovascular disease is associated with low HDL.
3. (Currently Amended) A method as defined in claim 1 wherein said one or more alleles are selected from the group consisting of: intron 1 (707) allele 2; intron 8 (3707) allele 2; intron 8 (3946) allele 2; promoter (VNTR) allele 2; insertion (307) allele 2; and intron 15 (493) allele 2, wherein detection of said allele indicates that the subject has a decreased predisposition to cardiovascular disease.
4. (Original) A method as defined in claim 1, wherein said detecting utilizes a technique selected from the group consisting of:
 - a) allele specific oligonucleotide hybridization;
 - b) size analysis;
 - c) sequencing;
 - d) hybridization;
 - e) 5' nuclease digestion;
 - f) single-stranded conformation polymorphism;
 - g) allele specific hybridization;
 - h) primer specific extension;
 - j) oligonucleotide ligation assay; and
 - k) RFLP analysis.

5. (Original) A method as defined in claim 1, further comprising amplifying the nucleic acid sample.

6.-33. (Withdrawn)

34. (Original) A method for identifying a subject suffering from a cardiovascular disorder that would be responsive to treatment with at least one cardiovascular disorder therapeutic, comprising:

detecting in a nucleic acid sample from said subject at least one CETP allele selected from the group consisting of intron 1 (707), intron 8 (3707), intron 8 (3946), promoter (VNTR), insertion (307), and intron 15 (493),
wherein said CETP allele is associated with a modified level of CETP activity.

35. (Original) A method as defined in claim 34 wherein the therapeutic modulates CETP activity.

36. (Original) A method as defined in claim 34 wherein the therapeutic modulates LDL levels.

37. (Original) A method as defined in claim 36 wherein the therapeutic is an HMG CoA reductase inhibitor.